Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-07-05
2011-07-05
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091310, C536S023100, C536S024500
Reexamination Certificate
active
07973017
ABSTRACT:
Agents that reduce the amount of IGFBP-2 and/or IGFBP-5 and that are known to be useful in the treatment of cancer result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. In overcoming this, the present invention provides a combination of therapeutic agents that is useful in the treatment of cancer. The combination includes an agent that reduces the amount of IGFBP-2 and/or IGFBP-5 and that stimulates expression of clusterin as a secondary effect, and an oligonucleotide that is effective to reduce the amount of clusterin in cancer cells. In some embodiments of the invention, the agent that reduces IGFBP-2 and/or IGFBP-5 is a bispecific antisense species. The oligonucleotide may be an antisense oligonucleotide or an RNAi oligonucleotide.
REFERENCES:
patent: 5417978 (1995-05-01), Tari et al.
patent: 5646042 (1997-07-01), Stinchcomb et al.
patent: 5721237 (1998-02-01), Myers et al.
patent: 5789389 (1998-08-01), Tarasewicz et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5855911 (1999-01-01), Lopez-Berestein et al.
patent: 5910583 (1999-06-01), Marks et al.
patent: 5929040 (1999-07-01), Werther et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6133246 (2000-10-01), McKay et al.
patent: 6172216 (2001-01-01), Bennett et al.
patent: 6284741 (2001-09-01), Werther et al.
patent: 6335194 (2002-01-01), Bennett et al.
patent: 6365345 (2002-04-01), Brysch et al.
patent: 6383808 (2002-05-01), Monia et al.
patent: 6451991 (2002-09-01), Martin et al.
patent: 6900187 (2005-05-01), Gleave et al.
patent: 7196067 (2007-03-01), Gleave et al.
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2002/0128220 (2002-09-01), Gleave
patent: 2003/0087857 (2003-05-01), Freier
patent: 2003/0105051 (2003-06-01), McSwiggen
patent: 2003/0158130 (2003-08-01), Gleave et al.
patent: 2003/0158143 (2003-08-01), Gleave et al.
patent: 2003/0166591 (2003-09-01), Gleave et al.
patent: 2004/0006106 (2004-01-01), Uesugi et al.
patent: 2004/0053874 (2004-03-01), Monia et al.
patent: 2004/0096882 (2004-05-01), Gleave et al.
patent: 2004/0220131 (2004-11-01), Jackson et al.
patent: WO 92/03470 (1992-03-01), None
patent: WO 92/03471 (1992-03-01), None
patent: WO 00/31048 (2000-06-01), None
patent: WO 00/34469 (2000-06-01), None
patent: WO 00/49937 (2000-08-01), None
patent: WO 00/69454 (2000-11-01), None
patent: WO 00/78341 (2000-12-01), None
patent: WO 01/01748 (2001-01-01), None
patent: WO 01/05435 (2001-01-01), None
patent: WO 01/46455 (2001-06-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 02/22635 (2002-03-01), None
patent: WO 02/22642 (2002-03-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 03/030826 (2003-04-01), None
patent: WO 03/035643 (2003-05-01), None
patent: WO 03/062421 (2003-07-01), None
patent: WO 03/072591 (2003-09-01), None
patent: WO 2004/018675 (2004-03-01), None
patent: WO 2004/018676 (2004-03-01), None
Opalinska, J. B. et al., Nature Reviews, vol. 1, pp. 503-514 (2002).
Chirila, T.V. et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Crooke, S.T., Antisense Res. & Application, Chapter 1, pp. 1-50, Ed. by S. Crooke, Publ. Springer-Verlag (1998).
Peracchi, A., Rev. Med. Virol., vol. 14, pp. 47-64 (2002).
Agrawal, S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Branch, A.D., Trends in Biochem. Sci., vol. 23, pp. 45-50 (1998).
Crooke, S., Ann. Rev. Medicine, vol. 55, pp. 61-95 (2004).
Peracchi et al., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Agrawal et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Chirila et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Opalinska et al., Nature Rev., vol. 1, pp. 503-514 (2002).
Holen et al., Nucleic Acids. Res., vol. 30, No. 8, pp. 1757-1766 (2002).
Jang, J.-H. et al., Gene delivery from polymer scaffolds for tissue engineering, Expert Rev. Med. Devices, vol. 1, No. 1, pp. 127-138 (2004).
Crooke, S., Progress in antisense technology, Ann. Rev. Medicine, vol. 55, pp. 61-95 (2004).
Agrawal, S. et al., Antisense therapeutics: Is it as simple as complementary base recognition? Molecular Med. Today, vol. 61, pp. 72-81 (2000).
Opalinska, J.B. et al., Nucleic acid therpaeutics: Basic principles and recent applications. Nature Rev., vol. 1, pp. 503-513 (2002).
Binkert, et al., Structure of the Human Insulin-Like Growth Factor Binding Protein-2 Gene, Molecular Endocrinology, 1992, pp. 826-836, vol. 6, No. 5.
Bubendorf, et al., Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays, Journal of the National Cancer Institute, Oct. 20, 1999, pp. 1758-1764, vol. 91, No. 20.
Corkins et al., Growth Stimulation by Transfection of Intestinal Epithelial Cells with an Antisense Insulin-Like Growth Factor Binding Protein-2 Construct, Biochemical and Biophysical Research Communications, Jun. 26, 1995, pp. 707-713, vol. 211, No. 3.
Forsyth, et al., Growth Inhibition of a Human Colon Cancer Cell Line by Antisense Oligonucleotide to IGFBP-2, 1995, p. A726, vol. 108, No. 4.
Gleave, et al., Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer, Current Drug Targets, 2003, pp. 209-221, vol. 4, No. 3.
Miyake, et al., Castration-Induced Up-Regulation of Insulin-Like Growth Factor Binding Protein-5 Potentiates Insulin-Like Growth Factor-I Activity and Accelerates Progression to Androgen Independence in Prostate Cancer Models, Cancer Research, Jun. 1, 2000, pp. 3058-3064, vol. 60.
Steller et al., Insulin-like growth factor II mediates epidermal growth factor-Induced mitogenesis in cervical cancer cells, Proc. Natl. Acad. Sci.-Cell Biology, Dec. 1995, pp. 11970-11974, vol. 92.
Wang et al., Correlation of Glioma Cell Regression with Inhibition of Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein-2 Expression, Neuroendrocrinology, 1997, pp. 203-211, vol. 66.
Shimasaki et al., Identification of Five Different Insulln-like Growth Factor Binding Proteins (IGFBP's) from Adult Rat Serum and Molecular Cloning of a Novel IGFBP-5 in Rat and Human, Journal of Biological Chemistry, Jun. 5, 1991, pp. 10646-10653, vol. 266, No. 16.
Zangemeister-Wittke et al., A Novel Bispecific Antisense Oligonucleotide Inhibiting both bcl-2 and bcl-xL Expression Efficiently Induces Apoptosis in Tumor Cells, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, Jun. 2000, pp. 2547-2555, vol. 6, No. 6.
Andress et al. , Human Osteoblast-derived Insulin-like Growth Factor (IGF) Binding Proteln-5 Stimulates Osteoblast Mitogenesis and Potentiates IGF Action, Journal of Biological Chemistry, Nov. 5, 1992, pp. 22467-22472, vol. 267, No. 31.
Andrea D. Branch, A good antisense molecule is hard to find, TIBS, Feb. 1998, pp. 45-50.
Crooke et al., Basic Principles of Antisense Therapeutics, Antisense Research and Application, 2004, pp. 1-50, Publisher: Springer.
Jen et al., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, Stem Cells 2000, 2000, pp. 307-319, vol. 18.
Opalinska et al., Nucleic-acid therapeutics: Basic principles and recent applications, Nature Reviews, Jul. 2002, pp. 503-514, vol. 1.
Agrawal et al., Antisense therapeutics: is it as simple as complementary base recognition?, Molecular Medicine Today, Feb. 2000, pp. 72-81, vol. 6.
Angelloz-Nichoud et al., Autocrine Regulation of Cell Proliferation by the Insulin-Like Growth Factor (IGF) and IGF Binding Protein-3 Protease System in a Human Prostate Carcinoma Cell Line (PC-3), Endocrinology, 1995, pp. 5485-5492, vol. 136, No. 12.
Boudon et al., Secretion of Insulin-Like Growth Factors and Their Binding Proteins by Human Normal and Hyperplastic Prostatic Cells in Primary Culture, Journal of Clinical Endocrinology and Metabolism, Feb. 1, 1996, pp. 612-617, vol. 81, No. 2.
Cucco et al., In Vitro and In Vivo Reversal of Multidrug Resistance in a Human Leukemia-resistant Cell Line by mdr1Antisense Oligodeoxynucleotides, Cancer Research, Oct. 1, 1996, pp. 4332-4337, v
Larson & Anderson LLC
The University of British Columbia
Zara Jane
LandOfFree
Treatment of cancer by inhibition of IGFBP's and clusterin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of cancer by inhibition of IGFBP's and clusterin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cancer by inhibition of IGFBP's and clusterin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2717867